- Home
- ERAS vs HFRO Comparison
ERAS vs HFRO Comparison
Compare ERAS & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- HFRO
- Stock Information
- Founded
- ERAS 2018
- HFRO 2000
- Country
- ERAS United States
- HFRO United States
- Employees
- ERAS N/A
- HFRO N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- HFRO Finance/Investors Services
- Sector
- ERAS Health Care
- HFRO Finance
- Exchange
- ERAS Nasdaq
- HFRO Nasdaq
- Market Cap
- ERAS 439.7M
- HFRO 362.0M
- IPO Year
- ERAS 2021
- HFRO N/A
- Fundamental
- Price
- ERAS $2.44
- HFRO $6.43
- Analyst Decision
- ERAS Buy
- HFRO
- Analyst Count
- ERAS 6
- HFRO 0
- Target Price
- ERAS $3.67
- HFRO N/A
- AVG Volume (30 Days)
- ERAS 2.1M
- HFRO 179.8K
- Earning Date
- ERAS 11-07-2025
- HFRO 01-01-0001
- Dividend Yield
- ERAS N/A
- HFRO 8.87%
- EPS Growth
- ERAS N/A
- HFRO N/A
- EPS
- ERAS N/A
- HFRO N/A
- Revenue
- ERAS N/A
- HFRO N/A
- Revenue This Year
- ERAS N/A
- HFRO N/A
- Revenue Next Year
- ERAS N/A
- HFRO N/A
- P/E Ratio
- ERAS N/A
- HFRO N/A
- Revenue Growth
- ERAS N/A
- HFRO N/A
- 52 Week Low
- ERAS $1.01
- HFRO $4.24
- 52 Week High
- ERAS $3.31
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- ERAS 59.41
- HFRO 50.34
- Support Level
- ERAS $2.18
- HFRO $6.40
- Resistance Level
- ERAS $2.65
- HFRO $6.51
- Average True Range (ATR)
- ERAS 0.15
- HFRO 0.10
- MACD
- ERAS -0.03
- HFRO -0.02
- Stochastic Oscillator
- ERAS 55.79
- HFRO 27.48
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.